![]() Alferon N Injection is a natural-source, multi-species alpha interferon approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older. Alferon N Injection is the registered trademark for its injectable formulation of natural alpha interferon. ![]() Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS) and is an experimental drug in the United States undergoing clinical development for the treatment of certain cancers and ME/CFS. ![]() The Company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules and Alferon N Injection (Interferon Alfa-N3). The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.AIM ImmunoTech Inc. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. ![]() Many of these forward-looking statements involve a number of risks and uncertainties. Words such as “may,” “will,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.įor more information, please visit and connect with the Company on Twitter, LinkedIn, and Facebook. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. With central IRB approval, our team is working toward getting our pre-selected sites open so that patient enrollment and dosing can be up and running as quickly and efficiently as possible.”ĪIM ImmunoTech Inc. We continue to be encouraged by the pilot data demonstrated to date and believe Ampligen has the potential to meet an important growing unmet medical need, with a patient population that exceeds several million in the United States alone, with even more worldwide. Equels commented, “This is an important step forward in the development of Ampligen as a potential therapeutic for the treatment of post-COVID chronic fatigue-like conditions. Other study outcomes include: change from baseline to week 6 in PROMIS ® Fatigue Score change from baseline to weeks 6 and 13 in distance traveled during a Six-Minute Walk Test proportion of subjects that surpass 54 meters in the Six-Minute Walk Test at the end of 12-week treatment phase change from baseline to weeks 6 and 13 in PROMIS ® Cognitive Function Score and change from baseline to weeks 6 and 13 in PROMIS ® Sleep Disturbance Score.ĪIM Chief Executive Officer Thomas K. The primary outcome measure of the study is change from baseline to week 13 in PROMIS ® Fatigue Score. AIM ImmunoTech has reported positive safety data from the third cohort in a Phase I AMP-COV-100 clinical study of its intranasal therapy, Ampligen, as a potential prophylaxis or treatment for Covid-19 and various respiratory viral diseases. The AMP-518 clinical trial is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in patients experiencing the post-COVID condition of fatigue. With this approval in hand, AIM is moving forward with the start-up process for the study’s planned clinical sites. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, today announced central Institutional Review Board (“IRB”) approval for the protocol of its Phase 2 study evaluating Ampligen ® as a therapeutic for patients with post-COVID conditions (“AMP-518”). OCALA, Fla., Ap(GLOBE NEWSWIRE) - AIM ImmunoTech Inc. Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditions
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |